These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 10853880)
1. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Shimamoto J; Ieiri I; Urae A; Kimura M; Irie S; Kubota T; Chiba K; Ishizaki T; Otsubo K; Higuchi S Eur J Clin Pharmacol; 2000 Apr; 56(1):65-8. PubMed ID: 10853880 [TBL] [Abstract][Full Text] [Related]
2. Is diclofenac a valuable CYP2C9 probe in humans? Morin S; Loriot MA; Poirier JM; Tenneze L; Beaune PH; Funck-Brentano C; Jaillon P; Becquemont L Eur J Clin Pharmacol; 2001; 56(11):793-7. PubMed ID: 11294368 [TBL] [Abstract][Full Text] [Related]
3. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203 [TBL] [Abstract][Full Text] [Related]
4. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388 [TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640 [TBL] [Abstract][Full Text] [Related]
7. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Aithal GP; Day CP; Leathart JB; Daly AK Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605 [TBL] [Abstract][Full Text] [Related]
8. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091 [TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Zhou D; Lu Y; Steiner MS; Dalton JT Antimicrob Agents Chemother; 2000 Oct; 44(10):2659-63. PubMed ID: 10991840 [TBL] [Abstract][Full Text] [Related]
12. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997 [TBL] [Abstract][Full Text] [Related]
13. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175 [TBL] [Abstract][Full Text] [Related]
14. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164 [TBL] [Abstract][Full Text] [Related]
15. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J Biochem Pharmacol; 1999 Sep; 58(5):787-96. PubMed ID: 10449188 [TBL] [Abstract][Full Text] [Related]
16. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Damkier P; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487 [TBL] [Abstract][Full Text] [Related]
17. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828 [TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364 [TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512 [TBL] [Abstract][Full Text] [Related]
20. [Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced influenza-virus-associated encephalopathy]. Funato T; Kozawa K; Kaku M Rinsho Byori; 2002 Feb; 50(2):140-5. PubMed ID: 11925850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]